Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lattice Biologics's share price for the quarter that ended in Jun. 2021 was C$0.04. Lattice Biologics's Shares Outstanding (EOP) for the quarter that ended in Jun. 2021 was 128.22 Mil. Therefore, Lattice Biologics's market cap for the quarter that ended in Jun. 2021 was C$5.13 Mil.
Lattice Biologics's quarterly market cap
increased
from Dec. 2020 (C$5.77 Mil) to Mar. 2021 (C$7.05 Mil) but then
declined
from Mar. 2021 (C$7.05 Mil) to Jun. 2021 (C$5.13 Mil).
Lattice Biologics's annual market cap
declined
from Sep. 2018 (C$3.74 Mil) to Sep. 2019 (C$2.80 Mil) but then
increased
from Sep. 2019 (C$2.80 Mil) to Sep. 2020 (C$5.13 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lattice Biologics's Enterprise Value for Today is C$5.10 Mil.
Lattice Biologics Market Cap Historical Data
The historical data trend for Lattice Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Lattice Biologics's Market Cap
For the Medical Devices subindustry, Lattice Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lattice Biologics's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where Lattice Biologics's Market Cap falls into.
Lattice Biologics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lattice Biologics's Market Cap for the fiscal year that ended in Sep. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lattice Biologics (TSXV:LBL.H) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lattice Biologics Market Cap Related Terms
Thank you for viewing the detailed overview of Lattice Biologics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Lattice Biologics (TSXV:LBL.H) Business Description
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:LBL.H has been successfully added to your 